Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: Hepatic population derived from human pluripotent stem cells is effectively increased by selective removal of undifferentiated stem cells using YM155

Fig. 4

Characterization of hepatic induction following YM155 treatment at stage II. At stage III, the homogeneity of the cell population was observed in 5 and 10 nM YM155 treatment of stage II (day 6), but nonhepatocyte-like cells (arrow) derived from USCs still appeared in 1 nM YM155 like DMSO (a). Expression of hepatic endoderm (AFP, ALB and HNF4A), ectoderm (PAX6, NESTIN and NCAM) and mesoderm (MSX1 and TNNT2) marker genes was estimated at 15 days of differentiation (b). At stage IV, albumin-positive cells were measured by flow cytometer (n = 3) (c) and enzyme activities of CYP1A2 and CYP3A4 were also estimated with QIA7-iHeps (d). QIA7-iHeps showed weak immunoreactivity against CYP1A2 but strong against CYP3A4 (e). *p < 0.05 (significantly different from the control). AFP alpha-fetoprotein, ALB albumin, DMSO dimethyl sulfoxide, HNF4A hepatocyte nuclear factor 4 alpha, PAX6 paired box protein Pax-6, MSX1 Msh homeobox-1, NCAM neural cell adhesion molecule, TNNT2 cardiac muscle troponin T

Back to article page